7th May 2019 09:39
LONDON (Alliance News) - Syncona Ltd on Tuesday said it was encouraged by portfolio firm Blue Earth Diagnostics prostate cancer imaging tests results.
The healthcare company said that a trial on 58 patients of Blue Earth's radiohybrid PSMA-targeted agent, rhPSMA-7, demonstrated sensitivity of 72%, specificity of 93% and diagnostic accuracy 86%, when compared to histopathological findings.
Martin Murphy, Chief Executive of Syncona Investment Management Ltd, said: "We are encouraged by these results, which provide further evidence to support the potential clinical utility of rhPSMA-7 in both high-risk primary and recurrent prostate cancer."
"While Blue Earth will next look to test this hypothesis in its own clinical trial, this data reinforces our belief that this PSMA agent is one of the leading assets in the space and should enable Blue Earth to extend its leading position in prostate cancer diagnostics."
Syncona owns a 89% stake in Blue Earth Diagnostics.
Syncona shares were trading up 2.3% at 247.50 pence each.
Related Shares:
Syncona